Cabazitaxel + carboplatin in treatment of mCRPC

A newly published article in Lancet Oncology has suggested that “taxane–platinum combinations have a clinically beneficial role in advanced prostate cancer”. … READ MORE …

The APCCC in Basel, Switzerland: Day 2

The second day of the APCCC here in Basel ran for 10 hours and encompassed a total of six sessions, as follows: … READ MORE …

PARP inhibitor has positive outcomes in Phase III trial in selected men with mCRPC

According to a media release issued jointly yesterday by AstraZeneca and Merck, treatment with the PARP inhibitor olaparib (Lynparza) has demonstrated “positive results from the Phase III PROfound trial … in [a subset of] men with metastatic castration-resistant prostate cancer (mCRPC).” … READ MORE …

FDA approves darolutamide for treatment of nmCRPC

Bayer’s US pharmaceutical division has announced that the US Food and Drug Administration (FDA) has approved darolutamide — their formerly investigational androgen receptor inhibitor — for the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Early data from the LuPIN trial in men with mCRPC

A lot of people are hopeful that treatment with a new form of targeted nuclear radiation therapy — lutetium-177 PSMA 617 (177Lu PSMA) — will be able to significantly extend survival of men with metastatic, castration-resistant prostate cancer (mCRPC) … READ MORE …

FDA “fast tracks” ARV-110 for the treatment of mCRPC

At the end of May, just prior to the annual meeting of ASCO, the US Food and Drug Administration (FDA) granted fast track designation to an investigational  agent called ARV-110 for treatment of metastatic, castration-resistant prostate cancer (mCRPC). … -READ MORE …

Phase III trial of olaparib in first-line treatment of mCRPC

Unfortunately we don’t always hear about some interesting clinical trials as early as we would like to. The following is a case in point. … READ MORE …